AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02272881 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: wound management
Description: Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
Study NCT01866410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02488902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02488902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 25mg
Description: Tafenoquine 25mg
Study NCT02488902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 50mg
Description: Tafenoquine 50mg
Study NCT02488902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg
Description: Tafenoquine 100 mg
Study NCT02488902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg
Description: Tafenoquine 200 mg
Study NCT02488902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg
Description: Mefloquine 250 mg
Study NCT01931137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Dose level of 8100 nmol will be orally administered as one tablet per dose.
Study NCT04887974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: canine retraction
Description: Canine retraction using elastomeric chains activated every 4 weeks, using power arms to direct force through the center of resistance and TADs for direct anchorage.
Study NCT01309828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Fixed-dose combination tablets.
Study NCT01309828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil and hydrochlorothiazide
Description: Fixed-dose combination tablets.
Study NCT03360656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal Thermal Regulating Device
Description: Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours
Study NCT00738920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Administered Cognitive Behavior Therapy
Description: This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
Study NCT00738920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist Administered Cognitive Behavior Therapy
Description: This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
Study NCT00738920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Education and Supportive Therapy
Description: This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
Study NCT02323139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and LDE255
Description: Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
Study NCT01625286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363 when combined with weekly paclitaxel.
Description: AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Study NCT01625286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363 when combined with weekly paclitaxel.
Description: AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Study NCT01625286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5363when combined with weekly paclitaxel.
Description: Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Study NCT01625286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A placebo in combination with weekly paclitaxel.
Description: Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Study NCT02252497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator : Tranexamic Acid (Exacyl)
Description: * 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours .
Study NCT02252497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator : physiologic serum
Description: * 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours
Study NCT03881579 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nurse-led supportive care assessment
Description: Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
Study NCT03881579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led supportive care assessment
Description: Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
Study NCT02100527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: 200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
Study NCT02100527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
Study NCT00931021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline (Chantix)
Description: 2 mg
Study NCT00931021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: 21 mg
Study NCT05867602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
Study NCT00651833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
Study NCT04257318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrating Relaxation Tool
Description: Use of a Vibrating Relaxation Tool in case of pain during pregnancy
Study NCT03509935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Ultrasound Group
Description: Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced.
Study NCT01271335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase
Description: Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
Study NCT00811083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMSA - dimercaptosuccinic acid
Description: dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
Study NCT00256100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Sodium
Description: The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
Study NCT01384864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proflavine
Description: 2-6 ml of 0.01% proflavine
Study NCT03948737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Tocopherol
Description: all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
Study NCT03948737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha-Tocopherol
Description: all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
Study NCT03948737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Study NCT03948737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Study NCT02268331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Surveillance
Study NCT02268331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Surveillance
Study NCT00299273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie high fat/protein diet
Description: 6 weeks of caloric restriction (50%) on a high fat/protein diet
Study NCT03503474 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, this is observational only
Study NCT00529802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: take 2 tablets of RAD001 once a day by mouth (10 mg per day)
Study NCT00827359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablet form taken orally once a day
Study NCT03251209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical practice
Description: Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
Study NCT03251209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical practice
Description: Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
Study NCT03251209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice
Description: Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
Study NCT03251209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videotherapy
Description: Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
Study NCT03251209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videotherapy
Description: Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
Study NCT02409537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: red wine
Description: the individuals were given red wine to consume for 1 month then a wash out period of 1 month
Study NCT04473404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius DB-B5 - 2 billion CFU/day
Description: The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
Study NCT04473404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius DB-B5 - 10 billion CFU/day
Description: The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
Study NCT04473404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
Study NCT02817789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor alone
Description: 180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
Study NCT02817789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination lysine acetylsalicylate - clopidogrel
Description: 75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
Study NCT02409537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: the individuals were given resveratrol for 1 month and then 1 month wash out period
Study NCT02438449 — intervention group
Intervention type: PROCEDURE
Intervention: Breast Reconstruction Surgery
Description: AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
Study NCT02801045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art therapy
Description: Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~* humanistic phenomenological focus~* transpersonal therapeutic bound~* transdisciplinarity in the artistic approach~* integrative-relational specialized counseling of the grief, loss and trauma aspects.
Study NCT04045392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
Study NCT03057548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryo or RF Ablation only of Pulmonary Veins
Description: Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone
Study NCT03057548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW
Description: Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)
Study NCT03727204 — intervention group
Intervention type: PROCEDURE
Intervention: On-pump cardiac surgery
Description: All participants will undergo on-pump cardiac surgery
Study NCT03424876 — intervention group
Intervention type: DRUG
Intervention: Imatinib 400mg
Description: exposure 400 mg/day or 600mg/day,
Study NCT02409537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: the individuals were given placebo for 1 month
Study NCT03424876 — intervention group
Intervention type: DRUG
Intervention: Sunitinib 37.5Mg Oral Capsule
Description: exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
Study NCT03661294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GE Healthcare Metabolic Oxygenator
Study NCT02688101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DpC
Description: iron chelator
Study NCT03612401 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mirabegron
Description: Beta-3 adenoreceptor agonist
Study NCT00886782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cdc7-inhibitor
Description: Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
Study NCT01260246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: pill, 100mg/daily for 6 months
Study NCT01260246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo match for 6 months
Study NCT00107419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
Study NCT03321019 — intervention group
Intervention type: DRUG
Intervention: Capsaicin
Description: Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
Study NCT03321019 — intervention group
Intervention type: DEVICE
Intervention: Resistive respiratory loads
Description: Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
Study NCT03321019 — intervention group
Intervention type: OTHER
Intervention: Event-related evoked potential using electroencephalography (EEG).
Description: The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
Study NCT03321019 — intervention group
Intervention type: PROCEDURE
Intervention: Fluoroscopic swallow evaluation
Description: Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
Study NCT02068404 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Study NCT04716673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Down-phase targeted auditory stimulation
Description: The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.
Study NCT01963676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study NCT01963676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Study NCT04313023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: 20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
Study NCT04313023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for inhalation
Study NCT02067988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 microspheres hepatic radioembolization.
Description: Holmium-166 microspheres hepatic radioembolization.
Study NCT00919802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
Study NCT00919802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline as a nasal spray
Description: A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
Study NCT04004273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 24 moderate-intensity exercise training sessions over six weeks (four times per week; \~50 min per session)
Study NCT00681824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Description: Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
Study NCT00681824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
Study NCT04769128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy programe
Description: thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
Study NCT04769128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy programe
Description: thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.